Connect with us

CBD News

NORML Interviews Dr. Sisley On Cannabis Research Resistance And Her DEA Lawsuit

Published

on

NORML-Interview-with-Dr-Sisley-on-Cannabis

Dr. Sue Sisley and the Scottsdale Research Institute filed a lawsuit in July against the United States Drug Enforcement Agency over marijuana research. As a news report by NBC News reports, “About a decade ago, Sisley decided to study pot’s psychiatric effects to see if she could prove what her patients were experiencing. But, because of marijuana’s federal status as an illegal drug, this turned out to be far from a simple task.”

In a recent blog post, NORML shared its interview with Dr. Sisley, in which she discussed the litigation and marijuana. Here are a few of the main highlights of the interview, which can be read in full here: https://blog.norml.org/2019/09/20/why-dr-sue-sisley-sued-the-dea-for-stonewalling-cannabis-research/.

When asked when the DEA or the University of Mississippi have provided any lab results concerning the cannabis powders that she is giving patients, Dr. Sisley responded:

“That’s one of the problems, and one of our legal arguments: There’s no transparency. Normally, when you do clinical trials — and for years I did trials for Big Pharma — you get a complete drug master file that would give you all the details about the drug: its properties, how it was manufactured, etcetera. There’s none of that available.”

According to the interview, Dr. Sisley also tested the DEA’s ground-up weed powder. When she stated,

“We did. We were the first scientists to do independent secondary testing [on the DEA’s cannabis]. We sent it out to other DEA-licensed labs and did three independent rounds of testing, just to confirm that it was even cannabis.” She added, “The testing did confirm that the [batch sent by NIDA] has cannabinoids, some very minute quantities of terpenes in it, and that it was cannabis. It was just diluted with a lot of extraneous plant material. So, that’s one way that they can really sabotage your study outcomes because the study drug is issued to patients by weight.”

The interview then addressed the question of issuing cannabis to patients by weight as a way to sabotage a medical marijuana study. Dr. Sisley responded:

“In the last study we just completed, each patient got 1.8 grams [of cannabis] per day. So, if half of the weight of the study drug isn’t just the flower, then it’s all this other plant material — stems sticks, leaves — that’s weighing it down. And you can imagine how that would harm your efficacy data, because suddenly the patient may need to smoke two bowls just to get any therapeutic benefit, and by then they’ve developed so much bronchial irritation that they often can’t reach that therapeutic threshold.”

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.